Fund shareholders of Halozyme Therapeutics Inc
ISIN US40637H1095 · United States · LEI 529900242I3SV9AGM753
- Fund shareholders
- 520
- Of which ETFs
- 141 379 other funds
- Value held
- 3.1B $ 1.6M € · 424.1M SEK
- Share of capital
- 42.9 % of 113.5M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Xtrackers S&P MidCap 400 Scored & Screened ETF DBX ETF Trust | 207 | 14.4K $ | 0.37 % | 0.00 % | as of Feb 27, 2026 ↗ |
| Avantis Inflation Focused Equity ETF American Century ETF Trust | 174 | 12.1K $ | 0.13 % | 0.00 % | as of Feb 28, 2026 ↗ |
| AQR CVX Fusion Fund AQR Funds | 149 | 9.6K $ | 0.03 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Small Company Growth Portfolio Wilshire Mutual Funds Inc | 144 | 9.3K $ | 0.04 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Invesco QQQ Hedged Advantage ETF Invesco Actively Managed Exchange-Traded Fund Trust | 144 | 9.2K $ | 0.07 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Fidelity Flex Mid Cap Focused Index Fund Fidelity Salem Street Trust | 144 | 9.2K $ | 0.07 % | 0.00 % | as of Apr 30, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 108 | 6.9K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Mid-Cap 1.5x Strategy Fund Rydex Variable Trust | 98 | 6.3K $ | 0.19 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SA Franklin Tactical Opportunities Portfolio SUNAMERICA SERIES TRUST | 85 | 5.4K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| VIP Hedged Equity Portfolio Variable Insurance Products Fund VI | 50 | 3.2K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Kennedy Capital Small Cap Growth Fund INVESTMENT MANAGERS SERIES TRUST II | 37 | 2.4K $ | 0.48 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Columbia Research Enhanced Mid Cap ETF Columbia ETF Trust I | 27 | 1.7K $ | 0.06 % | 0.00 % | as of Mar 31, 2026 ↗ |
| MUTUAFONDO SALUD, FI MUTUACTIVOS, S.A., S.G.I.I.C. | 560.4K € | 3.14 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE VI, FI GESTION BOUTIQUE VI / FUNDAMENTAL APPROACH ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 332.3K € | 5.29 % | as of Dec 31, 2025 ↗ | ||
| GVC GAESCO ZEBRA US SMALL CAPS LOW POPULARITY, FI GVC GAESCO GESTIÓN, SGIIC, S.A. | 222K € | 1.70 % | as of Dec 31, 2025 ↗ | ||
| GESIURIS HEALTHCARE & INNOVATION FI GESIURIS ASSET MANAGEMENT, SGIIC, S.A. | 217.7K € | 1.22 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE VI, FI GESTION BOUTIQUE VI / KALDI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 143.2K € | 1.47 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE IV, FI GESTION BOUTIQUE IV/ALCLAM US EQUITIES ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 85.9K € | 1.29 % | as of Dec 31, 2025 ↗ | ||
| COMPROMISO MEDIOLANUM, FI MEDIOLANUM GESTION, S.G.I.I.C., S.A. | 57.5K € | 0.14 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE VII, FI GESTION BOUTIQUE VII / TOP QUALITY OPPORTUNITIES ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 26.9K € | 2.12 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| GESTION BOUTIQUE VI, FI GESTION BOUTIQUE VI / FUNDAMENTAL APPROACH ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 5.29 % | as of Dec 31, 2025 ↗ |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 3.17 % | as of Mar 31, 2026 ↗ |
| MUTUAFONDO SALUD, FI MUTUACTIVOS, S.A., S.G.I.I.C. | 3.14 % | as of Dec 31, 2025 ↗ |
| The Future Fund Long/Short ETF NORTHERN LIGHTS FUND TRUST II | 3.12 % | as of Feb 28, 2026 ↗ |
| Leadershares Alphafactor Tactical Focused ETF Two Roads Shared Trust | 3.05 % | as of Apr 30, 2026 ↗ |
| Infrastructure Capital Small Cap Income ETF Series Portfolios Trust | 3.03 % | as of Feb 28, 2026 ↗ |
| Congress Mid Cap Growth Fund Professionally Managed Portfolios | 2.58 % | as of Apr 30, 2026 ↗ |
| Invesco Biotechnology & Genome ETF Invesco Exchange-Traded Fund Trust | 2.57 % | as of Apr 30, 2026 ↗ |
| M3Sixty Income and Opportunity Fund 360 Funds | 2.43 % | as of Feb 28, 2026 ↗ |
| Congress SMid Growth ETF Professionally Managed Portfolios | 2.30 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 506 | +14 | 47,994,208 | +6.4 % |
| 2026Q1 | 492 | -28 | 45,112,481 | -3.9 % |
| 2025Q4 | 520 | +9 | 46,966,645 | -5.9 % |
| 2025Q3 | 511 | +13 | 49,908,576 | -13.4 % |
| 2025Q2 | 498 | +30 | 57,626,404 | -1.4 % |
| 2025Q1 | 468 | -30 | 58,425,945 | -3.2 % |
| 2024Q4 | 498 | +7 | 60,334,863 | +0.8 % |
| 2024Q3 | 491 | +18 | 59,870,540 | -1.9 % |
| 2024Q2 | 473 | -1 | 61,022,777 | +0.8 % |
| 2024Q1 | 474 | +9 | 60,558,972 | -2.3 % |
| 2023Q4 | 465 | 62,016,133 |
Institutional managers
626 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 13,265,053 | 857.3M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 4,937,854 | 319.1M $ | as of Mar 31, 2026 |
| Invesco Ltd. | 4,012,494 | 259.3M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 2,913,109 | 188.3M $ | as of Mar 31, 2026 |
| Boston Partners | 2,683,683 | 173.4M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 2,562,309 | 165.6M $ | as of Mar 31, 2026 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2,525,975 | 163.3M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,505,786 | 162M $ | as of Mar 31, 2026 |
| SNYDER CAPITAL MANAGEMENT L P | 2,323,077 | 150.1M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 2,079,827 | 134.4M $ | as of Mar 31, 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,918,149 | 124M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 1,868,708 | 120.8M $ | as of Mar 31, 2026 |
| ALLIANCEBERNSTEIN L.P. | 1,736,501 | 116.9M $ | as of Mar 31, 2026 |
| ROYAL LONDON ASSET MANAGEMENT LTD | 1,610,553 | 104.1M $ | as of Mar 31, 2026 |
| JUPITER ASSET MANAGEMENT LTD | 1,608,256 | 103.9M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 1,584,961 | 102.4M $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 1,535,737 | 99.3M $ | as of Mar 31, 2026 |
| FIRST TRUST ADVISORS LP | 1,482,340 | 95.8M $ | as of Mar 31, 2026 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,465,283 | 94.7M $ | as of Mar 31, 2026 |
| GW&K Investment Management, LLC | 1,393,875 | 90.1K $ | as of Mar 31, 2026 |
| LSV ASSET MANAGEMENT | 1,371,558 | 88.6K $ | as of Mar 31, 2026 |
| MIZUHO MARKETS AMERICAS LLC | 1,323,544 | 85.5M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,289,533 | 83.3M $ | as of Mar 31, 2026 |
| CONGRESS ASSET MANAGEMENT CO | 1,280,592 | 82.8M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 1,233,658 | 79.7M $ | as of Mar 31, 2026 |
Declared shareholders of Halozyme Therapeutics Inc
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Vanguard Capital Management | 5.21 % | 6,173,547 | as of Mar 31, 2026 · SCHEDULE 13G |
Funds holding the debt of Halozyme Therapeutics Inc
53 funds declare 77 bond lines of this company. The table shows the 25 largest holdings. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
Cite this page
Titelia. "Fund shareholders of Halozyme Therapeutics Inc". https://titelia.com/en/stocks/halozyme-therapeutics-inc-US40637H1095